J Exp Med. 2025 Sep 1;222(9):e20241454. doi: 10.1084/jem.20241454. Epub 2025 Jun 6. Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control Abstract Conventional mRNA cancer vaccines can expand the quantity of tumor-specific CD8 T cells, but their effector function might be compromised. Specific cytokine signaling may enhance T cell differentiation for better tumor killing. We screened various cytokines and identified IL-12 as a potent adjuvant for mRNA vaccines, though with significant systemic toxicity. To balance efficacy and toxicity, we developed a membrane-tethered IL-12 (mtIL12) adjuvant mRNA vaccine. This design restricts mtIL12 expression to the surface of antigen-presenting cells, thereby selectively activating antigen-specific T cells without affecting bystander T or NK cells. mtIL12 adjuvant mRNA vaccination induced a unique pre-effector T cell subset that gives rise to highly responsive effector T cells, resulting in superior anti-tumor activity. Moreover, this approach overcame immune checkpoint therapy resistance and prevented cancer metastasis. Our study highlights that next-generation mRNA vaccines encoding membrane-tethered cytokine adjuvants can generate potent effector T cells, offering effective tumor control with reduced toxicity. Product: Wholesale Best Excipient For DNA/RNA Delivery,professional Excipient For DNA/RNA Delivery Suppliers

Bioact Mater. 2024 Jun 21:40:430-444. doi: 10.1016/j.bioactmat.2024.06.021. eCollection 2024 Oct. Kneadable dough-type hydrogel transforming from dynamic to rigid network to repair irregular bone defects Abstract Irregular bone defects, characterized by unpredictable size, shape, and depth, pose a major challenge to clinical treatment. Although various bone grafts are available, none can fully meet the repair needs of the defective area. Here, this study fabricates a dough-type hydrogel (DR-Net), in which the first dynamic network is generated by coordination between thiol groups and silver ions, thereby possessing kneadability to adapt to various irregular bone defects. The second rigid covalent network is formed through photocrosslinking, maintaining the osteogenic space under external forces and achieving a better match with the bone regeneration process. In vitro, an irregular alveolar bone defect is established in the fresh porcine mandible, and the dough-type hydrogel exhibits outstanding shape adaptability, perfectly matching the morphology of the bone defect. After photocuring, the storage modulus of the hydrogel increases 8.6 times, from 3.7 kPa (before irradiation) to 32 kPa (after irradiation). Furthermore, this hydrogel enables effective loading of P24 peptide, which potently accelerates bone repair in Sprague-Dawley (SD) rats with critical calvarial defects. Overall, the dough-type hydrogel with kneadability, space-maintaining capability, and osteogenic activity exhibits exceptional potential for clinical translation in treating irregular bone defects. Keywords: Dough-type hydrogel; Dynamic network; Irregular bone defect; Kneadable; Rigid network. Product: Manufacturer Of PEG Derivative By Structure,Wholesale PEG Derivative By Structure

Pharmaceutics. 2025 Jan 24;17(2):157. doi: 10.3390/pharmaceutics17020157. Engineering Lipid Nanoparticles to Enhance Intracellular Delivery of Transforming Growth Factor-Beta siRNA (siTGF-β1) via Inhalation for Improving Pulmonary Fibrosis Post-Bleomycin Challenge Abstract Background/Objectives: Transforming Growth Factor-beta (TGFβ1) plays a core role in the process of pulmonary fibrosis (PF). The progression of pulmonary fibrosis can be alleviated by siRNA-based inhibiting TGF-β1. However, the limitations of naked siRNA lead to the failure of achieving therapeutic effect. This study aimed to design lipid nanoparticles (LNPs) that can deliver siTGF-β1 to the lungs for therapeutic purposes. Methods: The cytotoxicity and transfection assay in vitro were used to screen ionizable lipids (ILs). Design of Experiments (DOE) was used to obtain novel LNPs that can enhance resistance to atomization shear forces. Meanwhile, the impact of LNPs encapsulating siTGF-β1 (siTGFβ1-LNPs) on PF was investigated. Results: When DLin-DMA-MC3 (MC3) was used as the ILs, the lipid phase ratio was MC3:DSPC:DMG-PEG2000:cholesterol = 50:10:3:37, and N/P = 3.25; the siTGFβ1-LNPs could be stably delivered to the lungs via converting the siTGFβ1-LNPs solution into an aerosol (atomization). In vitro experiments have confirmed that siTGFβ1-LNPs have high safety, high encapsulation, and can promote cellular uptake and endosomal escape. In addition, siTGFβ1-LNPs significantly reduced inflammatory infiltration and attenuated deposition of extracellular matrix (ECM) and protected the lung tissue from the toxicity of bleomycin (BLM) without causing systemic toxicity. Conclusions: The siTGFβ1-LNPs can be effectively delivered to the lungs, resulting in the silencing of TGF-β1 mRNA and the inhibition of the epithelial-mesenchymal transition pathway, thereby delaying the process of PF, which provides a new method for the treatment and intervention of PF. Keywords: design of experiments (DOE); lipid nanoparticles (LNPs); pulmonary fibrosis (PF); siRNA delivery; transforming growth factor β1 (TGF-β1). Product: Wholesale Best Excipient For DNA/RNA Delivery,professional Excipient For DNA/RNA Delivery Suppliers

Join Us at TIDES Europe 2025 in Congress Center Basel! Mark your calendars!TIDES Europe2025—the premier event for oligonucleotide and peptide therapeutics—is coming to Basel, Switzerland, on 11-13 November 2025. Visit SINOPEG at Booth #333 to explore cutting-edge solutions in: Custom PEG Derivatives (mPEG, heterobifunctional PEGs, branched PEGs) Lipid Nanoparticles (LNPs) & Lipidoids for nucleic acid delivery Innovative Linker Technologies & ADC Payloads Why Stop By? Discuss your formulation challenges with our PEGylation experts Discover high-purity excipients for mRNA, siRNA, and peptide therapies Learn how our GMP-grade materials accelerate preclinical-to-commercial transitions Spotlight Case Study: Ask us about our role in developing temperature-stable LNP formulations for a global COVID-19 vaccine partner! Schedule a 1:1 Meeting: Avoid the crowds—reserve your private session today: sales@sinopeg.com Can't attend? Explore our solutions online: http://www.sinopeg.com Let's shape the future of oligonucleotide and peptide therapeutics together! See you at #333. #TIDES2025 DrugDiscovery #LNPs #mRNA #PeptideTherapeutics #BiotechInnovation

Molecules. 2017 Jul 15;22(7):1190. doi: 10.3390/molecules22071190. Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length Abstract A set of lipopeptides was recently reported for their broad-spectrum antiviral activity against viruses belonging to the Paramyxoviridae family, including human parainfluenza virus type 3 and Nipah virus. Among them, the peptide with a 24-unit PEG linker connecting it to a cholesterol moiety (VG-PEG24-Chol) was found to be the best membrane fusion inhibitory peptide. Here, we evaluated the interaction of the same set of peptides with biomembrane model systems and isolated human peripheral blood mononuclear cells (PBMC). VG-PEG24-Chol showed the highest insertion rate and it was among the peptides that induced a larger change on the surface pressure of cholesterol rich membranes. This peptide also displayed a high affinity towards PBMC membranes. These data provide new information about the dynamics of peptide-membrane interactions of a specific group of antiviral peptides, known for their potential as multipotent paramyxovirus antivirals. Keywords: antiviral; cholesterol; membranes; paramyxoviruses; peptides. PEG Linker: Various Kingds And Grades Of Such Monodispersed Are Readily Avaliable| SINOPEG

Join Us at 2025 CPHI Worldwide Europe! SINOPEG's booth no. 8.0T48 Exciting news! 2025 CPHI Worldwide Europe is just around the corner, taking place October 28–30 at Messe Frankfurt. SINOPEG will be showcasing cutting-edge drug delivery system (DDS) solutions at Booth 8.0T48.    As your trusted partner in specialty chemicals and advanced drug delivery systems, we’re eager to share innovations that drive industry progress. Why visit us? Explore our latest portfolio of PEG derivatives, lipids, and custom synthesis services Discuss tailored solutions for your R&D and manufacturing challenges Connect face-to-face with our technical experts We warmly welcome friends, partners, and industry peers from around the globe to drop by!    Let’s collaborate to shape the future of pharma. Dates: October 28–30, 2025 Venue: Messe Frankfurt Our Booth: T48 (Hall 8.0) Ready to meet? Simply stop by!

Join Us at CPhI Worldwide 2025–The Premier Global Pharma Event!   We are excited to invite you to visitSINOPEG at CPhI Worldwide 2025, the world‘s leading pharmaceutical industry gathering. This premier event brings together industry leaders, innovators, and experts from across the entire pharmaceutical supply chain—including APIs, formulations, biopharma, and outsourcing services.   Event Details: Date: October 28–30, 2025 Location: Frankfurt, Germany Booth: 8.0T48   At Booth 8.0T48, we will showcase our comprehensive technical capabilities and global service solutions tailored to meet the evolving needs of the pharmaceutical industry. This is a great opportunity to explore how SINOPEG can support your business with innovation, quality, and reliability.   We look forward to connecting with you, discussing potential collaborations, and sharing insights into the future of pharma.   Save the date and stop by—we can’t wait to welcome you!   Warm regards, The SINOPEG Team

J Pharm Sci. 2020 Feb;109(2):981-991.  doi: 10.1016/j.xphs.2019.10.052.  Epub 2019 Nov 2. Conjugation of Amine-Functionalized Polyesters With Dimethylcasein Using Microbial Transglutaminase Abstract Protein-polymer conjugates have been used as therapeutics because they exhibit frequently higher stability, prolonged in vivo half-life, and lower immunogenicity compared with native proteins.  The first part of this report describes the enzymatic synthesis of poly(glycerol adipate) (PGA(M)) by transesterification between glycerol and dimethyl adipate using lipase B from Candida antarctica.  PGA(M) is a hydrophilic, biodegradable but water insoluble polyester.  By acylation, PGA(M) is modified with 6-(Fmoc-amino)hexanoic acid and with hydrophilic poly(ethylene glycol) side chains (mPEG12) rendering the polymer highly water soluble.  This is followed by the removal of protecting groups, fluorenylmethyloxycarbonyl, to generate polyester with primary amine groups, namely PGA(M)-g-NH2-g-mPEG12.  1H NMR spectroscopy, FTIR spectroscopy, and gel permeation chromatography have been used to determine the chemical structure and polydispersity index of PGA(M) before and after modification.  In the second part, we discuss the microbial transglutaminase-mediated conjugation of the model protein dimethylcasein with PGA(M)-g-NH2-g-mPEG12 under mild reaction conditions.  SDS-PAGE proves the protein-polyester conjugation. Keywords: CAL-B;  amine-functionalized polyester;  enzymatic polymerization;  microbial transglutaminase (mTGase);  poly(glycerol adipate) (M);  protein-polymer conjugate.